A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours

British Journal of Cancer

Volumn 90, Issue 4, 2004, Pages 800-804

  Wall, L ^a   Talbot, D C ^b   Bradbury D, P ^b   Jodrell, D I ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

BB 3644; Matrix metalloprotease inhibitor; Pharmacokinetics; Phase 1

Indexed keywords

BATIMASTAT; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; SOLIMASTAT; TUMOR NECROSIS FACTOR ALPHA; AMINOPYRIDINE DERIVATIVE; HYDROXAMIC ACID; METALLOPROTEINASE;

ADULT; AGED; ANOREXIA; ARTICLE; BONE PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG HALF LIFE; DYSPEPSIA; FEMALE; HUMAN; LUNG EMBOLISM; MALAISE; MALE; MAXIMUM TOLERATED DOSE; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL TOXICITY; MYALGIA; NEUROLOGIC DISEASE; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; SOLID TUMOR; TASTE DISORDER; THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AMINOPYRIDINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROXAMIC ACIDS; MALE; MAXIMUM TOLERATED DOSE; METALLOENDOPEPTIDASES; MIDDLE AGED; MUSCULOSKELETAL DISEASES; NEOPLASMS; TREATMENT OUTCOME;

EID: 1642391046     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601594     Document Type: Article

References (11)

1. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD, Baillet M, Fielding JW (2002b) Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 86(12): 1864-1870
2. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA (2002a) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87(2): 161-167
3. Evans J, Stark A, Johnson CD, Daniel F, Carmichael J, Buckels J, Imrie CW, Brown P, Neoptolemos JP (2001) A phase II trial of marimastat in advanced pancreatic cancer. Br J Cancer 85(12): 1865-1870
4. Macaulay VM, O'Byrne KJ, Saunders MP, Braybrooke JP, Long L, Gleeson F, Mason CS, Harris AL, Brown P, Talbot DC (1999) Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 5: 513-520
5. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18(5): 1135-1149
6. Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, Berrington A, Cornish A, Lynch K, Rasmussen H, Kerr D, Cox D, Millar A (1998) Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumour markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 4(5): 1101-1109
7. Phuphanich S, Levin VA, Yung WK, Forsyth P, Maestro R, Perry J (2001) A multicenter, randomized, double-blind, placebo (PB) controlled trial of marimastat (MT) in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS) following completion of conventional, first-line treatment. Proc Am Soc Clin Onc 20: 205 (abstract)
8. Rosenbaum E, Sinibaldi V, Carducci MA, Zahurak M, Pili R, Denmeade S, Sokoll L, Epstein J, Pertin A, Eisenberger M (2003) Evidence of a dose/response relationship with marimastat in patients with biochemically relapsed prostate cancer. Proc Am Soc Clin Onc 22: 1762 (abstract)
9. Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Sadura A, Zee B (2002) Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J/ Clin Oncol 20(22): 4434-4439
10. Tierney GM, Griffin NR, Stuart RC, Kasem H, Lynch KP, Lury JT, Brown PD, Millar AW, Steele RJC, Parsons SL (1999) A pilot study of the safety and effects of the matrix metalloproteinase inhibitor Marimastat in gastric cancer. Eur J of Cancer 35(4): 563-568
11. Wojtowicz-Praga S, Torri J, Johnson M, Steen V, Marshall J, Ness E, Dickson R, Sale M, Rasmussen HS, Avanzato Chiodo T, Hawkins MJ (1998) Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 16(6): 2150-2156